Quarterly Result26 May 2026, 01:14 pm
Mahamaya Lifesciences FY26 Revenue Up 24.5% YoY to ₹32,887.30 Lakhs
AI Summary
Mahamaya Lifesciences Ltd reported its audited financial results for FY26, with revenue from operations increasing by 24.5% YoY to ₹32,887.30 Lakhs. EBITDA rose to ₹3,425.88 Lakhs, a 32.06% increase from FY25. Despite accounting and listing-related adjustments impacting profitability, the company achieved a PAT of ₹1,652.33 Lakhs. In H2 FY26, revenue from operations reached ₹16,580.93 Lakhs, with an improved EBITDA margin of 10.79%. The company focuses on expanding its sustainable crop care portfolio and strengthening its market presence.
Key Highlights
- FY26 revenue from operations increased by 24.5% YoY to ₹32,887.30 Lakhs.
- EBITDA for FY26 grew by 32.06% to ₹3,425.88 Lakhs.
- PAT for FY26 reached ₹1,652.33 Lakhs despite accounting adjustments.
- H2 FY26 revenue from operations was ₹16,580.93 Lakhs.
- The company is expanding its sustainable crop care portfolio.
Price Impact
More from MAHALIFE